Milbemite 0.1 % Solution is a Health Canada–registered veterinary drug (DIN 02246889) held by Elanco Canada Limited, containing Milbemycin Oxime. Health Canada lists its status as Cancelled Post Market (status date 30 Jul 2026). Nexara Health has matched 10 registrations of Milbemycin Oxime across 1 other regulated market.
Health Canada registration
| DIN | 02246889 |
|---|---|
| Brand name | Milbemite |
| Active ingredient | Milbemycin Oxime |
| Strength | 0.1 % |
| Dosage form | Solution |
| Route | Otic |
| Company | Elanco Canada Limited |
| Status | Cancelled Post Market — 30 Jul 2026 |
| Class | Veterinary |
| ATC | |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Status and company history
Changes Health Canada has recorded for this DIN, as observed by Nexara Health's weekly DPD comparison.
| Date | Field | From | To |
|---|---|---|---|
| 2026-09-03 | Status | Dormant | Cancelled Post Market |
| 2026-09-03 | Status | Dormant | Cancelled Post Market |
Milbemycin Oxime registered in other markets
10 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | milbemycin oxime | Elanco US Inc. | Tablet | FDA NDC | ||
| United States | Milbemycin Oxime | Zhejiang Hisun Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Hubei Honch Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC | ||
| United States | Milbemycin Oxime | Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd. | Powder | FDA NDC |
See every manufacturer of Milbemycin Oxime worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Milbemite (DIN 02246889) marketed in Canada?
No. Health Canada lists DIN 02246889 as Cancelled Post Market as of 30 Jul 2026.
Who holds the Canadian licence for this product?
Elanco Canada Limited is the company of record in the Health Canada Drug Product Database.
Is Milbemycin Oxime registered outside Canada?
Yes — Nexara Health has matched 10 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02246889, status date 2026-07-30; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02246889, status date 2026-07-30; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02246889, status date 2026-07-30; national medicine registries: FDA NDC. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.